A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
Salinger, David H; Blough, David K; Vicini, Paolo; Anasetti, Claudio; O'Donnell, Paul V; Sandmaier, Brenda M; McCune, Jeannine S.
Clin Cancer Res
; 15(16): 5280-7, 2009 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-19671874
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.
Glycodendrimer Nanocarriers for Direct Delivery of Fludarabine Triphosphate to Leukemic Cells: Improved Pharmacokinetics and Pharmacodynamics of Fludarabine.
Using Gold Nanoparticles as Delivery Vehicles for Targeted Delivery of Chemotherapy Drug Fludarabine Phosphate to Treat Hematological Cancers.
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Determination of fludarabine phosphate in human plasma using reversed phase high-performance liquid chromatography.
Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.